Home
About
Overview
Sharing Data
ORCID
Help
History (27)
Ethnic differences and functional analysis of MET mutations in lung cancer.
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study.
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
See All 27 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25.
View in:
PubMed
subject areas
Adenocarcinoma
Administration, Oral
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Female
Follow-Up Studies
Humans
Indazoles
International Agencies
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Phenylurea Compounds
Receptor Protein-Tyrosine Kinases
Salvage Therapy
Survival Rate
Treatment Outcome
authors with profiles
Clarissa C. Parker
Ravi Salgia
Thomas Hensing